Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | -0.36 | 0.09 | 0.04 |
| FCF Yield | -2.40% | -4.42% | -13.13% | -22.77% |
| EV / EBITDA | -29.12 | -12.57 | -6.51 | -4.54 |
| Quality | ||||
| ROIC | -10.66% | -24.65% | -18.64% | -23.98% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 124.06% |
| Cash Conversion Ratio | 0.88 | 0.61 | 1.11 | 1.57 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | 57.81% |
| Free Cash Flow Growth | -20.29% | 36.58% | 32.52% | -42.06% |
| Safety | ||||
| Net Debt / EBITDA | 6.09 | 1.26 | 1.55 | 1.86 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2,102.55 | 0.00 | -60.50 |